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Objective: Lennox-Gastaut syndrome (LGS) is a severe drug-resistant epilepsy (DRE) of childhood. The Vagus
Nerve Stimulator (VNS) is established as a safe and effective treatment for DRE. This study assesses efficacy and
tolerability of the auto-stimulation VNS models in pediatric patients with LGS.
Methods: This is a retrospective chart review of a cohort of pediatric patients (Age 1–18 years old) with LGS
implanted with an auto-stimulation VNS model at a single level four pediatric epilepsy center. Patient re
sponder’s rate was measured as seizure reduction over baseline and improvements in five quality-of-life mea
sures as reported by the patients and families. Efficacy and tolerability were assessed at 1, 3, 6, 12, 18 and 24
months compared to baseline.
Results: This cohort includes 71 consecutive children with Lennox-Gastaut syndrome who underwent implan
tation with one of two models of the auto-stimulation VNS. The average age of the children at implantation was
20.82 months. Of those patients, 55 % of patients achieved greater than 50 % seizure reduction at six months,
67.7 % at 12 months, and 65 % at 24 months. At 12 months 11 % of the patients were completely seizure free and
at 24 months 17 % were seizure free. By 24 months post implantation most of the patient families reported at
least a 50 % improvement rate in one or more of the quality-of-life measures. The most commonly reported
adverse events were dysphonia, paresthesia, and shortness of breath, all of which were tolerated and subsided by
24 months.
Significance: This study provides evidence that VNS models with the auto-stimulation paradigm based on
detection of tachycardia are well tolerated and effective in a pediatric population with LGS. Furthermore, this
study shows that for this population, the auto-stimulation models of the VNS may provide additional benefits
over the earlier VNS versions.

1. Introduction
The first vagus nerve stimulator (VNS) was approved in the United
States in 1997 for patients with drug resistant epilepsy (DRE). DRE is
defined by the International League Against Epilepsy (ILAE) as persis
tent seizures within a 12-month period during which time an individual
with epilepsy is treated with at least two properly chosen, properly
dosed and well-tolerated anti-seizure medications (ASM) [1]. VNS
therapy was reviewed by the American Academy of Neurology in 1997
[2], 1999 [3], and 2013 [4] and found to be both safe and effective in the
treatment of epilepsy. The observation that up to 82 % of epileptic

seizures are associated with an increase in heart rate [5] led to the
development of the auto-stimulation models of the VNS. The
auto-stimulation VNS models include a detect-and-respond mode that
detects ictal tachycardia and responds by delivering an extra stimulation
to the Vagus nerve. Like the older VNS models, in addition to the
auto-stimulation paradigm, these devices include a standard mode that
allows care takers to stimulate with a magnet over the device, triggering
a pulse of slightly higher current intensity over the baseline pulses. This
additional pulse is designed to disrupt the epilepctic discharge, thereby
ending the clinical seizure [6]. Two auto-stimulation VNS models are
currently available; in 2015, the Aspire SR VNS model was approved by
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followed our standard VNS programming protocol (Supplementary
Table 1). Note that patients varied in terms of the frequency and timing
of follow-up visits. As a result, the number of patients reported at each
time point varies.
The last four clinic visits before the Aspire SR™ or SenTiva™ VNS
models were implanted were analyzed to calculate an average number of
seizures per month. Following implantation, patient communications at
3, 6, 12, 18, and 24 months, or the communication time that was the
closest to each timeline benchmark, were analyzed for seizure type,
epilepsy type, seizure frequency, quality of life, and side effects. If the
patient had recorded communications with the epilepsy clinic one
month or less after the surgery, it was reported as an initial chart review.
Family and caretaker accounts were used to determine the average
number of seizures the patients had per month using the Epilepsy
Foundation seizure diary (https://diary.epilepsy.com/home) and
McHugh’s et al. classification of outcome after VNS insertion [24]. This
number was then compared to the average seizure frequency before
implantation with the auto-stimulation model. For the data analysis
patients were divided into the following groups: increase, no change, or
decrease in seizure activity. The patients with decrease in seizure ac
tivity were further subdivided into less than 50 % change, 50%–75%
change, 75%–90% change, greater than 90 % change, and seizure
freedom. All of the comparisons were made to the average seizure
burden prior to implantation with the auto-stimulation model of the
VNS. Quality-of-life measures assessed were alertness, sleep, develop
ment, academic performance, and attention. Outcomes were divided
into improvement, no improvement, or data not available.

the FDA followed, in 2017, by the SenTiva™ model. The FDA has
approved the use of VNS as an adjunctive therapy in adults and children
older than 4 years old with “partial onset seizures that are refractory to
medications”
(https://www.accessdata.fda.gov/cdrh_docs/pdf/p
970003s207b.pdf) currently known as focal seizures according to the
latest ILAE classification. Hamilton et al. showed that in an adult pop
ulation with epilepsy the Aspire SR™ model provided a significant
improvement in seizure control over the previous models (59 % of new
insertion had a >50 % seizure improvement and 71 % of patients with a
previously inserted VNS reported a >50 % seizure improvement on the
Aspire SR™ model) [7]. Tzadok et all presented very similar results in a
population of 46 patients, both pediatric and adult. In this paper that
included 13 children (< 12 years old) and 30 adolescents (13–18 years
old), the authors showed that approximately 60 % of patients had a 50 %
seizure reduction or better in patients newly implanted as well as those
who underwent replacement for a previous device. The patient’s epi
lepsy etiology was varied and included genetic, structural, infectious,
immune and unknown causes [8].
Lennox-Gastaut syndrome (LGS) is a severe childhood epilepsy with
onset typically before eight years of age that is almost always pharma
cologically resistant [9]. Different clinical characteristics are usually
required for a diagnosis of LGS to be made, including the presence of
multiple seizure types [10,11]. This epilepsy is now classified as a mixed
epilepsy syndrome in recognition of the fact that patients with LGS can
have both generalized and focal seizures [12]. The two most common
seizure types are tonic and atypical absence seizures. Electrographically,
seizures present as slow spike-wave complexes or generalized parox
ysmal fast activity [13]. Cognitive impairment and intellectual disability
are prominent features of the disorder and are clinically present in
20–60 % of patients at the time of diagnosis [10]. About 75 % of patients
with LGS have an identifiable etiology such as a genetic, structural, or
metabolic cause, with the most common cause being structural brain
abnormalities. In rare cases, progressive metabolic disorders have been
reported as a cause for LGS [9,14,15]. Due to the refractory nature of
LGS, patient treatment goals are shifted to reduce the number of sei
zures, especially atonic and tonic-clonic seizures, as those are often the
most incapacitating.
The efficacy of VNS therapy in LGS has been reported in several
studies. In a retrospective multicenter study of 50 LGS patients treated
with VNS, the median seizure reduction was 42 % after one month and
58.2 % after three months. When the data was further categorized by
seizure type, atonic seizures were found to decrease by a median of 47 %
after one month, 55 % after three months and 88 % after six months
[16]. Several other studies of patients with LGS implanted with the VNS
have reported 24 %–42 % reduction in seizures [17–23]. However, to
date no study has reported the efficacy of the auto-stimulation VNS
models when used in patients in LGS. In this study, we examine the
outcome of patients with LGS who were either newly implanted with the
auto-stimulation models of the VNS or switched from an older model to
the auto-stimulation model.

3. Results
A systematic chart review resulted in 71 consecutive patients with
LGS who were implanted with one of the auto-stimulation models of the
VNS. The reason for reimplantation with the auto-stimulation model
from the previous model was battery depletion in 100 % of the patients.
The average age at implantation was 20.82 months and the average age
of epilepsy onset was 18 months with the range being 0–14 years old and
the median being 10 months of age. 47 patients (66.2 %) were males. Of
the 71 patients, 35 (49.3 %) had a mixed epilepsy (patients with a
combination of both focal and generalized seizures), 10 (14.1 %) had a
focal epilepsy, and 26 (36.6 %) had a generalized epilepsy. The seizure
types were distributed as follows: 47 patients (66.2 %) had tonic-clonic
seizures, 21 (29.6 %) had clonic seizures, 41 (57.7 %) had atonic sei
zures, 56 (78.9 %) had myoclonic seizures, 25 (35.2 %) had absence
seizures, 27 (38 %) had epileptic spasms, 24 (33.8 %) had focal seizures
with impaired awareness and 59 (83.1 %) had tonic seizures. 47 patients
had genetic testing, with 26 patients having a confirmed genetic ab
normality. 11 patients had metabolic testing, of those 2 patients had
confirmed abnormalities and 65 patients had MRI studies, of those 46
patients had MRI structural abnormalities. Of the 71 patients, clinical
information was available for 26 patients at 1 month, 32 at 3 months, 44
at 6 months, 37 at 12 months, 24 at 18 months and 23 at 24 months.
At the start of the study the average number of anti-epileptic medi
cations (AED) per patient was 3.4 (median 3, range 0–7). There were 7
patients on ketogenic diet. At the last visit for each of the patients, the
average number of AEDs was 3.7 (median 4, range 0–8). There were 10
patients on ketogenic diet. There was no significant change in the
number of AEDs per patients (p = 0.7).
Of the 71 patients enrolled in the study, 26 had communication
within one month of implantation (reported as “initial chart review”). Of
those, 4 (15 %) had an increase in seizure frequency, 7 (27 %) had no
change, 15 (58 %) had a decrease and 3 (12 %) became completely
seizure free (Table 1 and Fig. 1). Nine (35 %) of these patients were
switched from the older VNS models to the auto-stimulation model. As
compared to the older VNS models, 7 had a decrease and 2 experienced
no change in seizure frequency. Of the patients that had a decrease, 3
had a <50 % decrease, 2 had a >50 % decrease, 1 had a >75 % decrease,

2. Methods
This is a retrospective chart review of 71 consecutive children be
tween the age of 1–18 years old with LGS at a single level four pediatric
epilepsy center who were implanted with an auto-stimulation VNS be
tween January 1, 2015 and December 31, 2019. For the purpose of data
gathering, all patient notes and communications in the form of clinic
visits or messages with the neurology clinic were included. All patients
were from a single quaternary epilepsy referral center in the Midwest
(Children’s Mercy Kansas City). All patients had a diagnosis of LennoxGastaut syndrome as determined by an epileptologist and were
implanted with an auto-stimulation model of the VNS (Aspire SR™ or
SenTiva™). Prior to implantation with the auto-stimulation model,
some patients had an older model of the VNS without the autostimulation feature while others were new implants. All patients
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categories (Fig. 3a).
At the 3-month follow up, 32 of the 71 patients had communications
with the epilepsy clinic. Of those, 4 (13 %) had an increase in seizure
frequency, 10 (31 %) had no change, 18 (56 %) had a decrease and 3
(9%) became seizure free (Table 1 and Fig. 1). Six (19 %) of these pa
tients had a VNS without auto-stimulation previously implanted. As
compared to the older VNS models, 3 of these patients had a decrease in
seizures and 3 experienced no change in seizure frequency. Of the pa
tients that had a decrease, 1 had <50 % decrease, 1 had >50 % decrease,
and 1 became seizure free (table 3 and Fig. 2). The majority of 32 pa
tients with a contact at the 3-month visit reported an improvement in
quality-of-life in at least one the variables assessed. The most common
improvement seen was sleep quality with 9 patients (27 %) reporting
improvements in this variable (Fig. 3b).
At the 6-month follow up visit, 44 of the 71 patients had communi
cation with the epilepsy clinic. Of those, 3 (7%) had an increase in
seizure frequency, 9 (21 %) had no change, 32 (73 %) had a decrease and
5 (11 %) became seizure free (Table 1 and Fig. 1). Thirteen (30 %) of
these patients were switched from an older version of the VNS to the
auto-stimulation model. As compared to the older VNS models, 1 patient
had an increase, 6 patients had a decrease and 6 experienced no change
in seizure frequency. Of the patients that had a decrease, 3 had <50 %
decrease, 1 had >50 % decrease, and 2 had >90 % decrease (Table 2 and
Fig. 2). The majority of the patients reported an improvement in qualityof-life in at least one of the measured variables. The most common im
provements seen in were in alertness and attention with 22 (51 %)
reporting improvements in each of those categories (Fig. 3c).
At the 12-month follow up visit, 37 of the 71 patients had commu
nication with the epilepsy clinic. Of those 6 (16 %) had an increase in
seizure frequency, 2 had no change (5%), 29 (78 %) had a decrease and 4

Table 1
Change in seizure frequency for all patients implanted with the auto-stimulation
VNS.
Seizure
Frequency
Initial
chart
review

3month
follow
up

6month
follow
up

12month
follow
up

18month
follow
up

24month
follow
up

10 (31
%)
18 (56
%)
4 (13
%)
8 (25
%)
3 (9%)

1 (4%)

1 (4%)

29 (78
%)
4 (11 %)

18 (75
%)
2 (8%)

19 (83
%)
4 (17 %)

12 (32
%)
7 (19 %)

1 (4%)

4 (17 %)

6 (25 %)

4 (17 %)

>90 %

1 (4%)

0

2 (11 %)

4 (17 %)

3 (13 %)

Seizure
free
Increase

3 (12
%)
4 (15
%)
26

3 (9%)

9 (21
%)
32 (73
%)
8 (18
%)
8 (18
%)
6 (14
%)
5 (11
%)
5 (11
%)
3 (7%)

2 (5%)

>75 %

7 (27
%)
15 (58
%)
5 (19
%)
4 (15
%)
2 (8%)

4 (11 %)

5 (21 %)

4 (17 %)

6 (16 %)

5 (21 %)

3 (13 %)

44

37

24

23

No change
Decrease
<50 %
>50 %

Total
patients

4 (13
%)
32

and 1 became seizure free (Table 2 and Fig. 2). In terms of quality-of-life,
the majority of patients with a contact at one month or less postimplantation reported improvements in at least one of the variables
assessed. The most common improvements reported were alertness and
attention, with 7 (27 %) reporting improvement in each of those

Fig. 1. Grouped data for all patients with implantation of the auto-stimulation VNS model. The x axis shows the percent decrease in seizure frequency at each clinical
contact. The y axis shows the percent of patient reporting the respective percent changes in seizure frequency.
Table 2
Change in seizure frequency for the patients who were switched from the traditional VNS to the auto-stimulation model.
Seizure Frequency

No change
Decrease
<50 %
>50 %
>75 %
>90 %
Seizure free
Increase
Total patients

Initial chart review

3-month follow up

6-month follow up

12-month follow up

18-month follow up

24-month follow up

2 (22 %)
7 (78 %)
3 (33 %)
2 (22 %)
1 (11 %)
0
1 (11 %)
0
9

3 (50
3 (50
1 (17
1 (17
0
0
1 (17
0
6

6 (46 %)
6 (46 %)
3 (23 %)
1 (8%)
0
2 (15 %)
0
1 (8%)
13

1 (8%)
8 (67 %)
0
6 (50 %)
0
2 (17 %)
0
3 (25 %)
12

0
5 (71 %)
1 (14 %)
1 (14 %)
1 (14 %)
1 (14 %)
1 (14 %)
2 (29 %)
7

1 (13
5 (63
1 (13
2 (25
2 (25
0
0
2 (25
8

%)
%)
%)
%)
%)

170
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Fig. 2. Patients switched from a traditional VNS model to the auto-stimulation model. The x axis shows the percent decrease in seizure frequency at each clinical
contact. The y axis shows the percent of patient reporting the respective percent changes in seizure frequency.

Fig. 3. Changes in quality-of-life. Changes in quality-of-life plotted at initial chart review 3a, 3-month 3b, 6-month 3c, 12-month 3d, 18-month 3e, and 24-month 3f.
The numbers within the bins represent the number of patients in each group.
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(11 %) became seizure free (Table 1 and Fig. 1). Twelve (32 %) of these
patients had a VNS without auto-stimulation previously implanted. As
compared to the older model of the VNS, 3 patients had an increase, 8
had a decrease, and 1 patient experienced no change in seizure fre
quency. Of the patients that had a decrease, 6 had a >50 % decrease, and
2 had a >90 % decrease (Table 2 and Fig. 2). The majority of patients
reported an improvement in quality-of-life in at least one of the
measured benchmarks. The most common improvement reported was in
developmental gains with 14 (39 %) reporting improvements in that
category (Fig. 3d).
At the 18-month follow up visit, 24 of the 71 patients had commu
nication with the epilepsy clinic. Of those, 5 (21 %) had an increase in
seizure frequency, 1 had no change (4%), 18 (75 %) had a decrease and 5
(21 %) became seizure free (Table 1 and Fig. 1). Seven (29 %) of these
patients had a VNS without auto-stimulation previously implanted. As
compared to the older VNS models, 2 had an increase and 5 had a
decrease in seizure activity. Of the patients that had a decrease, 1 had a
<50 % decrease, 1 had a >50 % decrease, 1 had a >75 % decrease, 1 had
a >90 % decrease, and 1 became seizure free (Table 2 and Fig. 2). Most
of the patients reported an improvement in quality-of-life in at least one
of the measured variables. The most common improvements observed
were in sleep quality and developmental gains with 13 (57 %) reporting
improvements in these two clinical areas (Fig. 3e).
Finally, 23 of the 71 patients had communications with the epilepsy
clinic at the 24-month visit. Of those, 3 (13 %) had an increase in seizure
frequency, 19 (83 %) had a decrease and 4 (17 %) became seizure free
(Table 1 and Fig. 1). Eight (35 %) of these patients had a VNS without
auto-stimulation previously implanted. As compared to the older VNS
models, 2 had an increase, 5 had a decrease, and 1 had experienced no
change in seizure frequency. Of the patients that had a decrease, 1 had a
<50 % decrease, 2 had a >50 % decrease, and 2 had a >75 % decrease
(Table 2 and Fig. 2). The majority of patients reported an improvement
in quality-of-life in at least one of the measured variables. The most
common improvements reported were in attention and alertness with 12
(55 %) reporting improvements in each of those categories. It is worth
noting that a significant number of patients reported improvements in
sleep and developmental abilities, with 10 (43 %) patients reporting an
improvement in at least one of those variables (Fig. 3f).
Both models of the auto-stimulation VNS (Aspire SR™ and Sen
tiva™) were well tolerated. The most common side effects were voice
change, pain (discomfort with stimulation), and breathing issues
(Fig. 4). The side effects were most prevalent at the initial contact
following the surgery when 10 out of 26 patients reported some type of
side effects. With time, the side effects subsided, with only one patient
still reporting mild side effects at the 24-month visit. Four patients

required programing adjustments due to discomfort with stimulation.
No patients reported any side effects from the auto-stimulation.
4. Discussion
There is an overwhelming amount of data to suggest that LGS is
associated with a decreased quality-of-life. In 80–90 % of patients sei
zures will persist into adulthood [25–27]. Certain risk factors have been
shown to worsen the prognosis for LGS patients including a symptomatic
etiology, a history of infantile spasms, onset before 3 years of age and
cognitive dysfunction [28]. It is also known that LGS patients have a
5–17 % increase in mortality rate [28,]29. These deaths are directly
related to seizure frequency.
There has not previously been a study that has assessed the efficacy
of the auto-stimulation model of the VNS in children diagnosed with
LGS. One study of 347 children implanted with older models of the VNS
reported that the subset of patients with LGS responded well with 32.5
%, 37.6 %, and 43.8 % achieving greater than 50 % reduction in seizures
at 6, 12, and 24 months respectively [29]. Two studies to date have
examined the benefit of the new VNS devices in both children and
adults. Hamilton et al. showed that in an adult population with epilepsy
the Aspire SR™ model provided a significant improvement in seizure
control over the previous models [7]. Similarly, Tzadok et al. showed
that in a group of children and adults with epilepsy of various etiologies
the same Aspire SR™ model provided benefits for both the newly
implanted patients and those undergoing replacement of an older
model. They also showed that the benefits continued to accrue up to 24
months post implantation [8]. Closed loop VNS provides more accurate,
and timely delivery of electrical stimulation in response to ictal tachy
cardia allowing for a more precise duty cycle. The auto-stimulation
models are engineered to enforce a refractory period preventing over
stimulation as a result of either the normal cycle resuming or a second
ictal tachycardia [30,31].
In our study, the patient responder’s rate was higher with 55 %, 67.7
%, and 65 % of children achieving greater than 50 % reduction in sei
zures frequency at 6, 12, and 24 months respectively. In addition, 11 %
of the patients were completely seizure free at 12 months and 17 % were
seizure free at 24 months. Furthermore, when we separated the sub
group of patients that went from the older VNS models to an autostimulation model, we noted that an additional 60–70% of the pa
tients had a further reduction in seizure frequency over their baseline
with the older VNS models (Table 2). These data suggest that the newer
versions of the VNS with the auto-stimulation paradigm provide addi
tional seizure reduction over the pre-auto-stimulation models. In addi
tion, the majority of patients had an improvement in at least one

Fig. 4. Side-effects. Side effects were reviewed in all 71 patients. The visit time points are plotted on the x-axis and the number of patients reporting each side-effect
on the y-axis. Pain refers to discomfort associated with stimulation. Note that no patient reported any side effects from the auto-stimulation paradigm.
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measure related to quality-of-life with a positive trend over time. By 24
months post-implantation, most of the patient families reported at least
a 50 % improvement rate in one or more of the quality-of-life measures.
Consistent with previous observations of the pre-auto-stimulation VNS
models, very few patients experienced side effects and those that did had
a rapid resolution. The most common side effects reported were
dysphonia, paresthesia, and shortness of breath. None of the patients
died over the course of this study.
Overall the devices were well tolerated. While a little less than half of
the patients reported side effects at the initial contact following im
plantation, the side effects were well tolerated and steadily decreased
over time. None of the patients required removal or turning off the de
vice and only four patients required programing adjustments due to side
effects. The rate of side effects reported in our cohort is lower than
previously reported [32,33]. Our site follows a standardized protocol for
VNS programing (Supplement Table 1). This protocol has been effective
in minimizing side effects of the VNS and we believe that likely accounts
for the generally modest severity of the side effects reported in this
cohort. In summary, the data presented herein is consistent with the
auto-stimulation VNS model providing addition seizure reduction over
the older VNS models. Furthermore, in our cohort, the side effect profile
of the auto-stimulation model was better than previously reported for
the older models. However, as mentioned above, we cannot be sure that
the improved side effect profile can be ascribed to the auto-stimulation
model.
This study has limitations. Given the retrospective nature of the
study, it is subject to parental and physician bias. Furthermore, vari
ability in charting can be challenging in extracting information from the
medical records. For example, some of the epileptologists do not sys
tematically report the quality-of-life categories that the study was
designed to collect; this resulted in some patients missing data for these
variables. Also, quality-of-life is a highly subjective measure that is
subject to reporter bias. The study also relied on parental recall for
seizure frequency. Although this was mitigated by the fact that the data
was obtained at regular intervals, this type of recall is not as reliable as
actual seizure counts and journals. Finally, due to the retrospective
nature of this study, we could not control for AED changes that could
have confounded the data analysis and not all patients were seen at each
time point.

and approved the submitted version of the paper and accept re
sponsibility for its content.
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Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.seizure.2021.02.015.
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